Premium
Glipizide controlled‐release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes
Author(s) -
Bao YuQian,
Zhou Jian,
Zhou Mi,
Cheng YiJia,
Lu Wei,
Pan XiaoPing,
Tang JunLing,
Lu HuiJuan,
Jia WeiPing
Publication year - 2010
Publication title -
clinical and experimental pharmacology and physiology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.752
H-Index - 103
eISSN - 1440-1681
pISSN - 0305-1870
DOI - 10.1111/j.1440-1681.2010.05361.x
Subject(s) - glipizide , postprandial , acarbose , medicine , type 2 diabetes , area under the curve , glycemic , diabetes mellitus , combination therapy , pharmacology , insulin , gastroenterology , endocrinology
Summary 1. The aim of the present study was to compare the effects of glipizide controlled‐release (CR) tablets monotherapy with that of glipizide CR tablets plus acarbose on glycaemic variability in newly diagnosed Type 2 diabetes (T2DM) patients using a continuous glucose‐monitoring system (CGMS). 2. Forty newly diagnosed T2DM patients whose glycated haemoglobin A1c (HbA1c) levels ranged from 7.0% to 9.8% were randomized to either monotherapy or combination therapy. Overall glycaemic control and blood glucose variability were evaluated by CGMS parameters. 3. After 8 weeks treatment, fasting and postprandial blood glucose, HbA1c, glycated albumin (GA), mean blood glucose (MBG), mean amplitude of glycaemic excursions (MAGE), postprandial incremental area under the curve (AUC pp ) and homeostasis model assessment of insulin resistance decreased significantly in both groups ( P < 0.01). There was also a significant decrease in the mean of daily differences (MODD) in the combination therapy group. Mean changes in MBG, MAGE, MODD and AUC pp were significantly greater in the combination therapy group than in the monotherapy group (all P < 0.01), whereas no significant differences were found in the mean changes of HbA1c and GA. Multivariate regression analysis showed that the decrement in AUC pp was significantly associated with decreases in MAGE. 4. In conclusion, glipizide CR tablets alone or in combination with acarbose can improve overall blood glucose levels and glycaemic variability. Combination therapy using glipizide CR tablets and acarbose was more effective in reducing intraday and day‐to‐day glycaemic variability than glipizide CR tablet monotherapy.